Research progress on correlation between urine microbiota and benign prostatic hyperplasia
-
摘要: 良性前列腺增生是老年男性中一种常见疾病，发病率高，严重影响患者的生活质量。随着高通量测序技术的应用，越来越多的证据表明正常人尿液中存在丰富多样的微生物群，微生物群的失调会通过多个途径诱发前列腺炎症或前列腺上皮细胞的损坏，导致前列腺组织的增生和下尿路症状的加剧。本文从良性前列腺增生患者中尿液微生物群的特点、作用机制和预防及治疗等方面作一综述，为良性前列腺增生的预防和治疗提供新的方向及手段。Abstract: Benign prostatic hyperplasia(BPH) is prevalent among elderly men, leading to significant morbidity and diminished quality of life. With the application of high-throughput sequencing technology, more and more evidence has revealed the existence of abundant and diverse microbiota in the urine of healthy humans. The dysbiosis of the microbiota will induce prostatic inflammation or damage to prostate epithelial cells through multiple pathways, leading to hyperplasia of prostate tissue and exacerbation of lower urinary tract symptoms. In this review, we will summarize the characteristics of the urinary microbiota, its mechanism of action, and the prevention and therapy of BPH, aiming to provide novel directions and means for the prevention and treatment of BPH.
-
Key words:
- urine microbiota /
- benign prostatic hyperplasia /
- prostatic inflammation
-
-
[1] Bortnick E, Brown C, Simma-Chiang V, et al. Modern best practice in the management of benign prostatic hyperplasia in the elderly[J]. Ther Adv Urol, 2020, 12: 1756287220929486.
[2] GBD Benign Prostatic Hyperplasia Collaborators. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: A systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet Healthy Longev, 2022, 3(11): e754-e776. doi: 10.1016/S2666-7568(22)00213-6
[3] Li Y, Zhou X, Qiu S, et al. Association of sleep quality with lower urinary tract symptoms/benign prostatic hyperplasia among men in China: A cross-sectional study[J]. Front Aging Neurosci, 2022, 14: 938407. doi: 10.3389/fnagi.2022.938407
[4] Wada N, Abe N, Miyauchi K, et al. Risk factors for failure of long-term dutasteride add-on treatment to alpha-adrenergic antagonist for patients with lower urinary tract symptoms and benign prostatic enlargement[J]. Int Urol Nephrol, 2022, 54(1): 31-36. doi: 10.1007/s11255-021-03053-9
[5] Plochocki A, King B. Medical treatment of benign prostatic hyperplasia[J]. Urol Clin North Am, 2022, 49(2): 231-238. doi: 10.1016/j.ucl.2021.12.003
[6] Li J, Li Y, Cao D, et al. The association between histological prostatitis and benign prostatic hyperplasia: a single-center retrospective study[J]. Aging Male, 2022, 25(1): 88-93.
[7] Gandaglia G, Zaffuto E, Fossati N, et al. The role of prostatic inflammation in the development and progression of benign and malignant diseases[J]. Curr Opin Urol, 2017, 27(2): 99-106. doi: 10.1097/MOU.0000000000000369
[8] Cumpanas AA, Bratu OG, Bardan RT, et al. Urinary microbiota-are we ready for prime time?A literature review of study methods' critical steps in avoiding contamination and minimizing biased results[J]. Diagnostics(Basel), 2020, 10(6): 343.
[9] Pohl HG, Groah SL, Pérez-Losada M, et al. The urine microbiome of healthy men and women differs by urine collection method[J]. Int Neurourol J, 2020, 24(1): 41-51. doi: 10.5213/inj.1938244.122
[10] Bajic P, van Kuiken ME, Burge BK, et al. Male bladder microbiome relates to lower urinary tract symptoms[J]. Eur Urol Focus, 2020, 6(2): 376-382. doi: 10.1016/j.euf.2018.08.001
[11] Hrbacek J, Morais D, Cermak P, et al. Alpha-diversity and microbial community structure of the male urinary microbiota depend on urine sampling method[J]. Sci Rep, 2021, 11(1): 23758. doi: 10.1038/s41598-021-03292-x
[12] Karstens L, Asquith M, Davin S, et al. Does the urinary microbiome play a role in urgency urinary incontinence and its severity?[J]. Front Cell Infect Microbiol, 2016, 6: 78.
[13] Kumar T, Bryant M, Cantrell K, et al. Effects of variation in urine sample storage conditions on 16S urogenital microbiome analyses[J]. mSystems, 2023, 8(1): e0102922. doi: 10.1128/msystems.01029-22
[14] Maghini DG, Dvorak M, Dahlen A, et al. Quantifying bias introduced by sample collection in relative and absolute microbiome measurements[J]. Nat Biotechnol, 2024, 42(2): 328-338. doi: 10.1038/s41587-023-01754-3
[15] Karstens L, Asquith M, Caruso V, et al. Community profiling of the urinary microbiota: considerations for low-biomass samples[J]. Nat Rev Urol, 2018, 15(12): 735-749. doi: 10.1038/s41585-018-0104-z
[16] Eisenhofer R, Minich JJ, Marotz C, et al. Contamination in low microbial biomass microbiome studies: issues and recommendations[J]. Trends Microbiol, 2019, 27(2): 105-117. doi: 10.1016/j.tim.2018.11.003
[17] Kim JK, Song SH, Jung G, et al. Possibilities and limitations of using low biomass samples for urologic disease and microbiome research[J]. Prostate Int, 2022, 10(4): 169-180. doi: 10.1016/j.prnil.2022.10.001
[18] Carruthers LV, Moses A, Adriko M, et al. The impact of storage conditions on human stool 16S rRNA microbiome composition and diversity[J]. PeerJ, 2019, 7: e8133. doi: 10.7717/peerj.8133
[19] Gaulke CA, Schmeltzer ER, Dasenko M, et al. Evaluation of the effects of library preparation procedure and sample characteristics on the accuracy of metagenomic profiles[J]. mSystems, 2021, 6(5): e0044021. doi: 10.1128/mSystems.00440-21
[20] Nearing JT, Comeau AM, Langille MGI. Identifying biases and their potential solutions in human microbiome studies[J]. Microbiome, 2021, 9(1): 113. doi: 10.1186/s40168-021-01059-0
[21] 熊玉锋, 蔡贞, 李少川, 等. 生物信息学分析在病原微生物宏基因组高通量测序应用中的现状与挑战[J]. 中华医学杂志, 2023, 103(15): 1098-1102.
[22] Gu W, Miller S, Chiu CY. Clinical metagenomic next-generation sequencing for pathogen detection[J]. Annu Rev Pathol, 2019, 14: 319-338. doi: 10.1146/annurev-pathmechdis-012418-012751
[23] Liu JH, Huang T, Yao J, et al. Epitranscriptomic subtyping, visualization, and denoising by global motif visualization[J]. Nat Commun, 2023, 14(1): 5944. doi: 10.1038/s41467-023-41653-4
[24] Chen SF, Zhou YQ, Chen YR, et al. Fastp: an ultra-fast all-in-one FASTQ preprocessor[J]. Bioinformatics, 2018, 34(17): i884-i890. doi: 10.1093/bioinformatics/bty560
[25] Poulsen CS, Ekstrøm CT, Aarestrup FM, et al. Library preparation and sequencing platform introduce bias in metagenomic-based characterizations of microbiomes[J]. Microbiol Spectr, 2022, 10(2): e0009022. doi: 10.1128/spectrum.00090-22
[26] Lewis DA, Brown R, Williams J, et al. The human urinary microbiome; bacterial DNA in voided urine of asymptomatic adults[J]. Front Cell Infect Microbiol, 2013, 3: 41.
[27] Lee HY, Wang JW, Juan YS, et al. The impact of urine microbiota in patients with lower urinary tract symptoms[J]. Ann Clin Microbiol Antimicrob, 2021, 20(1): 23. doi: 10.1186/s12941-021-00428-9
[28] Okada K, Takezawa K, Tsujimura G, et al. Localization and potential role of prostate microbiota[J]. Front Cell Infect Microbiol, 2022, 12: 1048319. doi: 10.3389/fcimb.2022.1048319
[29] Honda-Takinami R, Hata JY, Matsuoka K, et al. Association between the presence of bacteria in prostate tissue and histopathology in biopsies from men not complaining of lower urinary tract symptoms[J]. Fukushima J Med Sci, 2022, 68(3): 161-167. doi: 10.5387/fms.2022-34
[30] Jain S, Samal AG, Das B, et al. Escherichia coli, a common constituent of benign prostate hyperplasia-associated microbiota induces inflammation and DNA damage in prostate epithelial cells[J]. Prostate, 2020, 80(15): 1341-1352. doi: 10.1002/pros.24063
[31] Ficarra V, Rossanese M, Zazzara M, et al. The role of inflammation in lower urinary tract symptoms(LUTS)due to benign prostatic hyperplasia(BPH)and its potential impact on medical therapy[J]. Curr Urol Rep, 2014, 15(12): 463. doi: 10.1007/s11934-014-0463-9
[32] Di Silverio F, Gentile V, De Matteis A, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis[J]. Eur Urol, 2003, 43(2): 164-175. doi: 10.1016/S0302-2838(02)00548-1
[33] Naiyila X, Li JZ, Huang Y, et al. A novel insight into the immune-related interaction of inflammatory cytokines in benign prostatic hyperplasia[J]. J Clin Med, 2023, 12(5): 1821. doi: 10.3390/jcm12051821
[34] Smith DK, Hasanali SL, Wang JJ, et al. Promotion of epithelial hyperplasia by interleukin-8-CXCR axis in human prostate[J]. Prostate, 2020, 80(12): 938-949. doi: 10.1002/pros.24026
[35] Russo GI, Bongiorno D, Bonomo C, et al. The relationship between the gut microbiota, benign prostatic hyperplasia, and erectile dysfunction[J]. Int J Impot Res, 2023, 35(4): 350-355. doi: 10.1038/s41443-022-00569-1
[36] Inouye BM, Hughes FM Jr, Sexton SJ, et al. The emerging role of inflammasomes as central mediators in inflammatory bladder pathology[J]. Curr Urol, 2018, 11(2): 57-72. doi: 10.1159/000447196
[37] Lloyd GL, Marks JM, Ricke WA. Benign prostatic hyperplasia and lower urinary tract symptoms: what is the role and significance of inflammation?[J]. Curr Urol Rep, 2019, 20(9): 54. doi: 10.1007/s11934-019-0917-1
[38] Contreras-Sanz A, Krska L, Balachandran AA, et al. Altered urothelial ATP signaling in a major subset of human overactive bladder patients with pyuria[J]. Am J Physiol Renal Physiol, 2016, 311(4): F805-F816. doi: 10.1152/ajprenal.00339.2015
[39] Kumar MN, Bhat S, Bhat KA, et al. Characterization of virulence factors and antibiotic resistance pattern of uropathogenic Escherichia coli strains in a tertiary care center[J]. F1000Res, 2022, 11: 1163. doi: 10.12688/f1000research.125596.2
[40] Huang Y, Xu W, Zhou RB. NLRP3 inflammasome activation and cell death[J]. Cell Mol Immunol, 2021, 18(9): 2114-2127. doi: 10.1038/s41423-021-00740-6
[41] Yu SH, Jung SI. The potential role of urinary microbiome in benign prostate hyperplasia/lower urinary tract symptoms[J]. Diagnostics(Basel), 2022, 12(8): 1862.
[42] Miyake M, Tatsumi Y, Ohnishi K, et al. Prostate diseases and microbiome in the prostate, gut, and urine[J]. Prostate Int, 2022, 10(2): 96-107. doi: 10.1016/j.prnil.2022.03.004
[43] Cho I, Blaser MJ. The human microbiome: at the interface of health and disease[J]. Nat Rev Genet, 2012, 13(4): 260-270. doi: 10.1038/nrg3182
[44] Siddiqui H, Lagesen K, Nederbragt AJ, et al. Alterations of microbiota in urine from women with interstitial cystitis[J]. BMC Microbiol, 2012, 12: 205. doi: 10.1186/1471-2180-12-205
[45] Magri V, Boltri M, Cai T, et al. Multidisciplinary approach to prostatitis[J]. Arch Ital Urol Androl, 2019, 90(4): 227-248. doi: 10.4081/aiua.2018.4.227
[46] Kaur G, Agarwal R, Sharma RK. Bacteriophage therapy for critical and high-priority antibiotic-resistant bacteria and phage cocktail-antibiotic formulation perspective[J]. Food Environ Virol, 2021, 13(4): 433-446. doi: 10.1007/s12560-021-09483-z
[47] Pathak-Vaidya P, Sharma S, Telang M. Bacteriophage as an antibacterial agent: a patent perspective[J]. Future Microbiol, 2021, 16: 1327-1339. doi: 10.2217/fmb-2021-0062
[48] Kwok M, McGeorge S, Mayer-Coverdale J, et al. Guideline of guidelines: management of recurrent urinary tract infections in women[J]. BJU Int, 2022, 130(Suppl 3): 11-22.
[49] Garretto A, Thomas-White K, Wolfe AJ, et al. Detecting viral genomes in the female urinary microbiome[J]. J Gen Virol, 2018, 99(8): 1141-1146. doi: 10.1099/jgv.0.001097
-
计量
- 文章访问数: 192
- 施引文献: 0
下载: